Navigation Links
Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
Date:10/9/2007

LOS ANGELES, Oct. 9 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP). "Raptor's management team was pivotal in getting two drugs approved and creating stockholder value while at BioMarin Pharmaceutical, a $2.4B biotech company and we believe they will do it again with Raptor," stated Ross Silver, Director of Research at Vista Partners. Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. For more information and to download the report; please visit the Vista Partners website at http://www.vistap.com.

About Raptor:

Raptor Pharmaceuticals Corp.'s (the "Company") sole business is its 100% ownership of Raptor Pharmaceutical Inc., a development stage biotechnology company which bioengineers novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins. The Company's preclinical programs target cancer, neurodegenerative disorders, infectious diseases and osteoporosis. HepTide(TM) utilizes engineered RAP-based peptides conjugated to drugs to target their delivery to the liver. In neurodegenerative diseases, engineered RAP peptides called NeuroTrans(TM) are currently undergoing evaluation at Stanford University in cell culture and preclinical models for their ability to enhance the transport of molecules from blood to brain. In osteoporosis, Raptor is testing the ability of WntTide(TM), which are Mesd and engineered Mesd-based peptides and act through LRP5, a known determinant of bone density, to combat osteoporosis and increase bone density. In an effort to protect its novel approach, Raptor currently has five patent applications in review in the U.S., and countries in Europe and Asia, as well as two provisional patent applications licensed from Washington University. In addition, the Company has recently submitted two new provisional patent applications in the U.S., the first of which covers a new family of RAP peptides, with the second application to further support and expand the Company's coverage in specific disease indications.

Contact:

Vista Partners LLC

Ross Silver

(415) 738-6229

info@vistap.com

http://www.vistap.com


'/>"/>
SOURCE Vista Partners LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Evista Not A Cure For Heart Disease
2. Spouses and other partners lower blood pressure says new research
3. Changing Partners may put Expectant Mothers at Risk
4. British Healthcare Mission Explores Partnership Possibilities With Indian Healthcare Sector
5. Partnership Between Diabetes India And Elsevier Announced
6. Betterment Of Health In Case Of Gay And Lesbian Civil Partnerships
7. Private Public Partnership To Tackle TB, In Karnataka
8. Courting HIV through Marriage or Partnership
9. Jealousy In Men Peaks When Partners Are Most Fertile
10. War Trauma Not Passed On To Partners And Children, Study
11. SRM Inst Signs Mou With Partners Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... , ... April 30, 2016 , ... Orlando-based Maximized Living ... they go for gold in Rio. Under the care of Maximized Living doctors ... , In an unprecedented showing, Maximized Living is sending the largest contingent of elite ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... notified by the Accreditation Council for Graduate Medical Education (ACGME) that it has ... This is the first accreditation of three residency programs that Memorial is currently ...
(Date:4/29/2016)... ... 2016 , ... Dr. Bernie Siegel, (M.D.) world ... and MIRACLES") addresses touchy topics related to Death live on Dr. Carol ... Bernie Siegel, author of a plethora of essential books-to-read for physicians and all ...
(Date:4/29/2016)... ... , ... Spine Team Texas, a comprehensive spine physician group specializing in the ... has been invited to be a featured speaker at the Texas Society of the ... 30, 2016. , Dr. R. Scott McPherson, a physical medicine and rehabilitation specialist, ...
(Date:4/29/2016)... ... , ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent of ... deaths. More than 10,000 people are expected to die of melanoma this year. The risk ... one of the most commonly diagnosed cancers in young women. A recent breakthrough in genetic ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... SHAWNEE, Kan. , April 27, 2016 /PRNewswire/ ... Martabano , a senior from the University of ... winner of the Bayer Excellence in Communication Award ... veterinary schools, which were awarded a total of ... Over the last four years, Bayer has provided ...
(Date:4/27/2016)... 27, 2016 Global  urinalysis ... billion by 2022, according to a new report ... (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... efficiency and accuracy delivered by the new generation ... novel urinalysis instruments and consumables. For instance, the ...
(Date:4/26/2016)... Hill-Rom Holdings, Inc. (NYSE: HRC ) invites you ... 41 st Annual Health Care Conference on Wednesday, May ... invited to listen to the live discussion via the internet ... http://edge.media-server.com/m/p/mr4uxgas . A recorded replay of the discussion will ... and accessible at the links above until August 1, 2016. ...
Breaking Medicine Technology: